{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(7)"],"submitter":["Wang L"],"pubmed_abstract":["<h4>Importance</h4>Neurofilament light in biofluids has been associated with progression of Parkinson disease (PD), but the association between neurofilament heavy (NfH) and progression of PD has not been investigated.<h4>Objective</h4>To evaluate the associations of cerebrospinal fluid (CSF) NfH (cNfH) levels and motor and cognitive progression in PD.<h4>Design, setting, and participants</h4>This cohort study used data from the Parkinson Progression Marker Initiative ranging from June 2010 to November 2018. Participants were recruited from 24 participating sites worldwide (United States, Europe, and Australia). Data were analyzed from October 20 to December 18, 2021.<h4>Exposures</h4>Concentrations of NfH in CSF.<h4>Main outcomes and measures</h4>The primary outcomes were Movement Disorde"],"journal":["JAMA network open"],"pagination":["e2223821"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9327574"],"repository":["biostudies-literature"],"pubmed_title":["Association of Cerebrospinal Fluid Neurofilament Heavy Protein Levels With Clinical Progression in Patients With Parkinson Disease."],"pmcid":["PMC9327574"],"pubmed_authors":["Zhang W","Mao C","Feng J","Liu CF","Cheng W","Liu F","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Association of Cerebrospinal Fluid Neurofilament Heavy Protein Levels With Clinical Progression in Patients With Parkinson Disease.","description":"<h4>Importance</h4>Neurofilament light in biofluids has been associated with progression of Parkinson disease (PD), but the association between neurofilament heavy (NfH) and progression of PD has not been investigated.<h4>Objective</h4>To evaluate the associations of cerebrospinal fluid (CSF) NfH (cNfH) levels and motor and cognitive progression in PD.<h4>Design, setting, and participants</h4>This cohort study used data from the Parkinson Progression Marker Initiative ranging from June 2010 to November 2018. Participants were recruited from 24 participating sites worldwide (United States, Europe, and Australia). Data were analyzed from October 20 to December 18, 2021.<h4>Exposures</h4>Concentrations of NfH in CSF.<h4>Main outcomes and measures</h4>The primary outcomes were Movement Disorde","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-05T12:10:57.917Z","creation":"2025-04-05T12:10:57.917Z"},"accession":"S-EPMC9327574","cross_references":{"pubmed":["35881392"],"doi":["10.1001/jamanetworkopen.2022.23821"]}}